Skip to main content
. Author manuscript; available in PMC: 2020 Feb 12.
Published in final edited form as: Oncogene. 2019 Aug 12;38(43):6913–6925. doi: 10.1038/s41388-019-0941-0

Fig. 2.

Fig. 2.

a mCol1a1 recipients develop more lung metastases, and 17β-estradiol (E2) significantly increases the size of lung metastases. i Photomicrographs of lung metastases (H&E) from recipients of orthotopic transplants treated as shown. Original magnifications, x40; scale bars, 500 μm. ii ER immunohistochemistry. Arrows point to ER+ metastatic cells. Original magnifications, x200; scale bars, 50 μm. iii Number of lesions per 4x field of view (FOV). iv Area of individual lesions. b Lungs of WT and mCol1a1 females which had been injected with 10 000 tumor cells into their tail veins displayed similar numbers (i) and sizes (ii) of lung lesions after 50 days. (Mean ± SEM; n=4–6 mice). Significant differences were determined by two-way ANOVA, followed by the Bonferroni post-test. Lower case letters denote significant differences with treatment in WT recipients and uppercase letters denote significant differences in mCol1a1 recipients (p < 0.02). * denotes significant differences between recipient genotypes (*p < 0.05, **p < 0.01, ****p < 0.0001).